What is it about?
A comparison of the cost of the two type of treatment, including treatment-related costs and hypoglycemia s
Featured Image
Why is it important?
Because the association Degludec/Liraglutide seems to be more expensive and in reality it is not so.
Perspectives
Following our analysis we expect a more favorable attitude of healt policies towards an increase of the use of this association.
Torre Enrico
Read the Original
This page is a summary of: Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes, ClinicoEconomics and Outcomes Research, July 2018, Dove Medical Press,
DOI: 10.2147/ceor.s169045.
You can read the full text:
Contributors
The following have contributed to this page
